Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses)

Panagopoulos, Ioannis; Mertens, Fredrik; Isaksson, Margareth; Mandahl, Nils

Published in:
Cancer Genetics and Cytogenetics

DOI:
10.1016/j.cancergencyto.2004.04.008

2005

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Absence of mutations of the *BRAF* gene in malignant melanoma of soft parts
(clear cell sarcoma of tendons and aponeuroses)

Ioannis Panagopoulos*, Fredrik Mertens, Margareth Isaksson and Nils Mandahl

Department of Clinical Genetics, Lund University Hospital, S-221 85 Lund, Sweden

Running title: No *BRAF* mutations in malignant melanoma of soft parts

Keywords: malignant melanoma of soft parts, clear cell sarcoma, translocation, *EWS* gene, *ATF1* gene, *BRAF* gene

*Corresponding author. Department of Clinical Genetics, University Hospital, SE-221 85 Lund, Sweden. Tel.: +46 46 172889; fax.: +46 46 131061.

E-mail adress: Ioannis.Panagopoulos@klingen.lu.se
Abstract

Malignant melanoma of soft parts (MMSP, also called clear cell sarcoma of tendons and aponeuroses) is cytogenetically characterized by the translocation t(12;22)(q13;q12) resulting in the chimeric EWSR1/ATF1 gene. MMSP shares a number of morphologic, histologic and immunohistochemical features with malignant melanoma of the skin, causing diagnostic difficulties in the distinction between MMSP and metastatic malignant melanoma with an unknown primary site. Recently, a high incidence of activating mutations in the kinase domain of the BRAF gene has been reported in malignant melanoma of the skin. The most common mutation (V599E) is the T1796A substitution in exon 15, leading to an exchange of valine for glutamic acid at position 599. Because of the extensive clinical, histologic and immunohistochemical similarities with melanoma, we decided to analyze whether MMSP also has mutations in the BRAF gene. Eight MMSP with an EWSR1/ATF1 chimeric transcript, one soft tissue metastasis of a malignant melanoma of the skin and one malignant melanoma cell line were examined. Both conventional melanomas had the exon 15 T1796A (V599E) mutation, but none of the MMSP was found to harbor any mutation in exon 11 or 15 of the BRAF gene. Our data further emphasize that MMSP and conventional malignant melanoma develop through different genetic pathways.
1. Introduction

Malignant melanoma of soft parts (MMSP, also called clear cell sarcoma of soft tissue) is a rare malignant soft tissue tumor first described by Enzinger [1] and has since been accepted as a distinct clinicopathological entity. The tumor is particularly associated with tendons and aponeuroses but other tumor locations have also been reported including the head and neck, ear, penis, kidney and colon [2]. MMSP is most commonly found in young adults between the age of 20 and 40 years, but has also been described in children and elderly [3,4]. Repeated local relapse is very common and with time, most tumors metastasize to lymph nodes, the lungs, skeleton, brain or liver [2]. Clonal chromosome abnormalities have been described in MMSPs and the translocation t(12;22)(q13;q12) seems to be pathognomonic [5,6]. The t(12;22) results in rearrangements of the \textit{EWSR1} gene on chromosome 22 and the \textit{ATF1} gene in 12q13 creating a chimeric \textit{EWSR1/ATF1} gene in which the 3’-terminal part of \textit{EWSR1} is replaced by the 3’-terminal part of \textit{ATF1} [7].

Histologically, the tumor shows a characteristic architecture of nests or short fascicles of epithelioid or spindle-shaped cells with clear to granular eosinophilic cytoplasm [2]. Immunohistochemically, the tumor cells express S-100 protein, HMB-45, vimentin, and the microphthalmia transcription factor, and synthesize melanin [2]. In a recent study, Segal et al. [8] used cDNA microarray to show that MMSP has a gene expression profile closely related to melanoma. Because MMSP shares a number of morphologic features with conventional malignant melanoma, there are diagnostic difficulties in the distinction between MMSP and metastatic malignant melanoma with an unknown primary site [2].

Recently, a high incidence of activating mutations in the \textit{BRAF} gene has been reported in melanoma cell lines, melanoma short term cultures, primary and metastatic
melanomas and nevi [9-12]. All the mutations were detected in the kinase domain of the
BRAF gene and found in exons 11 and 15 [9]. By far, the most common mutation
(V599E) is the T1796A single base substitution in exon 15, leading to an exchange of
valine for glutamic acid at position 599 [9]. Mutated BRAF proteins posses ten fold
higher basal kinase activity and are more than 100 times as efficient in transforming
NIH3T3 as compared to the wild-type BRAF gene [9].

Because of the extensive clinical, histologic and genetic similarities with
melanoma, we decide to analyze whether MMSP also has mutations in the BRAF gene.

2. Materials and methods
The material consisted of eight MMSP with an EWSR1/ATF1 chimeric transcript, the
melanoma cell line SK-MEL-28 and a soft tissue metastasis from a malignant
melanoma of the skin. The clinical data and the cytogenetic and molecular
identification of the fusion gene have been reported [13].

Tumor tissue pieces adjacent to those used for histological examination had
been frozen and stored at –80 °C. A one-step PCR was then performed using the primer
combination BRAFEx11For: ATCCCTCTCAGGCATAAGGTAATG and
BRAFEx11Rev: GCGAACAGTGAATATTTCCTTTGA and BRAFEx15For:
TGCTTGCTCTGATAGGAAAATGAG and BRAFEx15Rev:
TCTCAGGGGCAATAATTTAATCA for amplification of exons 11 and 15 of the
BRAF gene, respectively. The 50 µL reaction volume contained 20 mM Tris-HCl pH
8.4 (at 25°C), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM of each dNTP, 1 unit PlatinumTaq
DNA polymerase (Invitrogen), 0.5 µM of each of the forward and reverse primers and
300 ng of the genomic DNA. After an initial denaturation at 94°C for 5 minutes, 30
cycles of 1 minute at 94°C, 1 minute at 58°C, and 1 minute at 72°C were run using a
PCT-200 DNA Engine (MJ Research), followed by a final extension for 10 minutes at 72°C. For sequence analysis, the amplified fragments were run on 1.5% agarose gels, purified using the Qiagen gel extraction kit (Qiagen), and directly sequenced using the dideoxy procedure with an ABI Prism BigDye terminator cycle sequencing ready reaction kit (PE Applied Biosystems) and the same primers as for PCR on the Applied Biosystems Model 3100-Avant DNA sequencing system.

3. Results and discussion

None of the MMSP was found to harbor any mutations in exon 11 or 15 of the \textit{BRAF} gene whereas both malignant melanomas showed the previously described [9] exon 15 T1796A (V599E) mutation (Figure 1). Sequencing of the entire PCR products from the MMSP confirmed a wild-type sequence over the entire exons 11 and 15. Although the present study was limited to eight samples, it seems safe to conclude that \textit{BRAF} mutations are rare in MMSP. Consequently, if \textit{BRAF} is activated in MMSP (which remains to be determined) then that is unlikely to result from an intrinsic genomic mechanism. Our data further highlight the fact that MMSP is genetically different from conventional melanoma.

Acknowledgments

This work was supported by the Swedish Cancer Society, the Swedish Child Cancer Fund and Gunnar Nilsson Cancer Foundation.
References


Figure 1

Partial sequence chromatogram showing the *BRAF* exon 15 T1796A (V599E) mutation in the positive control and wild type sequence in an MMPS tumor biopsy.
Normal

T1796A mutation